Evidence map›Paper›PMID 34260521›Full record

SynthesisMedicine2021

Association between CASC16 rs4784227 polymorphism and breast cancer susceptibility: A meta-analysis.

Xiong-Shun Liang, Jun-Luan Mo, Li-Ming Hu, Chun-Mei Gong, Tao Liu, Wen-Xu Hong, Ji-Ye Yin, Zhao-Qian Liu, Hong-Hao Zhou

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xiong-Shun LiangShenzhen Center for Chronic Disease Control and Prevention, Shenzhen, Guangdong.
Jun-Luan MoShenzhen Center for Chronic Disease Control and Prevention, Shenzhen, Guangdong.
Li-Ming HuShenzhen Center for Chronic Disease Control and Prevention, Shenzhen, Guangdong.
Chun-Mei GongShenzhen Center for Chronic Disease Control and Prevention, Shenzhen, Guangdong.
Tao LiuShenzhen Center for Chronic Disease Control and Prevention, Shenzhen, Guangdong.
Wen-Xu HongShenzhen Center for Chronic Disease Control and Prevention, Shenzhen, Guangdong.
Ji-Ye YinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, PR China, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, PR China.
Zhao-Qian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, PR China, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, PR China.
Hong-Hao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, PR China, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, PR China.
Shenzhen Chronic Disease Prevention Center · CNCentral South University · CN

Funding

Guangdong Medical Science and Technology Research Fund No.B2021240Supported by the Sanming Project of Medicine in Shenzhen (No. SZSM201811057)
6 · The paper itself

Abstract

objectiveTo explore whether rs4784227 polymorphism of CASC16 is correlated with risk of breast cancer.

methodsRelevant studies up to December 24, 2020 were searched in PubMed, Embase, Web of Science, CNKI, VIP, and WANFANG databases. Data were analyzed by using Stata 12.0. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated, and country-based subgroup analyses were conducted. Sensitivity analysis was conducted to assess the stability of the results. Publication bias was assessed by using the Egger regression asymmetry test and visualization of funnel plots.

resultsSeven case-control studies enrolling 4055 breast cancer cases and 4229 controls were included. rs4784227 was found significantly associated with increased risk of breast cancer in a dominant (OR = 1.301, 95% CI = 1.190-1.423, P < .001), a recessive (OR = 1.431, 95% CI = 1.216-1.685, P < .001), and an allele model (OR = 1.257, 95% CI = 1.172-1.348, P < .001), while an over-dominant model showed that rs4784227 was correlated with decreased breast cancer risk (OR = 0.852, 95% CI = 0.778-0.933, P = .001).

conclusionThe rs4784227 polymorphism of CASC16 gene is correlated with breast cancer susceptibility.

Indexed as

AllelesApoptosis Regulatory ProteinsAsian PeopleBreast NeoplasmsCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansOdds RatioPolymorphism, Single NucleotideRisk FactorsTrans-ActivatorsApoptosis Regulatory ProteinsTOX3 protein, humanTrans-Activators

Identifiers

PMID34260521
PMCPMC8284751
OpenAlexW3181329461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.